

CLAIMS

We claim:


1. A compound which is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), or Formula (VI):




Formula (II),




Formula (III),



Formula (IV)



Formula (V), or



Formula (VI),

or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof,

wherein:

A^2 is N, CR^{2b}, or –C(=O)–;

A^3 is CR^3 or N, wherein R^3 is hydrogen;

A^4 is CR^8, wherein R^8 is hydrogen;

A^5 is CR^8, wherein R^8 is hydrogen;

A^6 is CR^8 or N, wherein R^8 is hydrogen;

each of W^1, W^2, W^3, and W^4 is independently N, CH, or CR^4, wherein R^4, at each occurrence, is independently halo;

Y is a linker having a length of up to 3 atoms, wherein Y is in the direction of (the ring comprising Z^1)-Y-(the ring comprising W^1), and is $–(CH_2)_{1-3}–$, $–O(CH_2)_{1-2}–$, or $–(CH_2)_{1-2}O–$;

each of Z^1, Z^2, Z^3, and Z^4 is independently N, CH, or CR^5, wherein R^5, at each occurrence, is independently R^9, -OH, $–OR^9$, halo, or CN, wherein R^9, at each occurrence, is independently C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{1a} is hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, or C_{1-6} hydroxyalkyl;

R^{1b} is hydrogen;

R^{2b} is R^9, $–OR^9$, halo, CN, $–C(O)NR^{10}R^{11}$, or $–NR^{10}R^{11}$, wherein R^9 is independently hydrogen, C_{1-6} alkyl, or 3-6 membered heterocycloalkyl, and wherein R^{10} and R^{11} are independently hydrogen or 3-6 membered heterocycloalkyl, or together with the N to which each is attached are combined to form a 3-6 membered heterocycloalkyl;

R^6 is CN, R^9, $–OR^9$, $–NR^{10}R^{11}$, or $–NR^{10}OR^9$, wherein R^9 is independently hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} hydroxyalkyl, or 3-6 membered heterocycloalkyl; and wherein each of R^{10} and R^{11} is independently hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{1-3} hydroxyalkyl, or together with the N to which each is attached are combined to form a 3-6 membered heterocycloalkyl; and


R^7 is an unsubstituted imidazolyl or unsubstituted triazolyl, or an imidazolyl or triazolyl, each substituted with 1-3 substituents independently selected from halo, CN, R^9, –OH, and $–OR^9$; wherein R^9 is independently C_{1-3} alkyl or C_{1-3} haloalkyl;

wherein each 3-6 membered heterocycloalkyl independently comprises 1-2 ring heteroatoms independently selected from oxygen, nitrogen, sulfur, and phosphorus.


2. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is a compound of Formula (II), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

3. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, wherein the compound is a compound of Formula (III), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

4. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 3, which is a compound of Formula (IIIa) or a compound of Formula (IIIb):




Formula (IIIa)




Formula (IIIb)

or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, and/or a mixture of stereoisomers thereof.


5. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 3, which is a compound of Formula (III-1), (IIIa-1), (IIIb-1), (III-2), (IIIa-2), (IIIb-2), (III-3), (IIIa-3), or (IIIb-3):




Formula (III-1)




Formula (IIIa-1)




Formula (IIIb-1)




Formula (III-2)




Formula (IIIa-2)




Formula (IIIb-2)



Formula (III-3)



Formula (IIIa-3)



Formula (IIIb-3)

or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

6. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is a compound of Formula (IV), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

7. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is a compound of Formula (V), or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

8. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is a compound of Formula (VI), or a

pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

9. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1 or claim 2, wherein R^{1a} is hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or C_{1-6} hydroxyalkyl.

10. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1 or claim 2, wherein R^{1a} is hydrogen, C_{1-3} alkyl, C_{3-4} cycloalkyl, or C_{1-3} hydroxyalkyl.

11. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1 or claim 2, wherein R^{1a} is:
(a) hydrogen, $–CH_3$, $–CD_3$, $–CH_2CH_3$, $–CD_2CD_3$, isopropyl, 2,3-dihydroxypropyl, or cyclopropyl; or
(b) $–CH_3$, $–CD_3$, or cyclopropyl; or
(c) $–CH_3$ or $–CD_3$; or
(d) cyclopropyl.

12. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1 and 3-5, wherein R^{2b} is:
(a) hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, -O-(3-6 membered heterocycloalkyl), halo, CN, $–C(O)NR^{10}R^{11}$, or $–NR^{10}R^{11}$;

wherein each of R^{10} and R^{11}, at each occurrence, is independently hydrogen or 3-6 membered heterocycloalkyl, or together with the N to which each is attached are combined to form a 3-6 membered heterocycloalkyl; or

(b) hydrogen, C_{1-3} alkyl, C_{1-3} alkoxy, -O-(3-4 membered heterocycloalkyl), halo, CN, –$C(O)NR^{10}R^{11}$, or –$NR^{10}R^{11}$;

wherein each of R^{10} and R^{11}, at each occurrence, is independently hydrogen or 3-4 membered heterocycloalkyl, or together with the N to which each is attached are combined to form a 4-6 membered heterocycloalkyl; or

(c) hydrogen, –CH_3, –CD_3, –CH_2CH_3, –CD_2CD_3, isopropyl, –OCH_3, –OCD_3, –OCH_2CH_3, –OCD_2CD_3, isopropoxy, 3-oxetanylalkoxy, chloro, CN, morpholino, piperazinyl, 3-oxetanylamino, or -$C(O)NH_2$; or

(d) CN.

13. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4, 6, and 8-12, wherein A^3 is CR^3, wherein R^3 is hydrogen.

14. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4, 6, 7, and 9-12, wherein A^6 is CR^8, wherein R^8 is hydrogen.

15. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4, 6, 7, and 9-12, wherein A^6 is N.

16. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4, 6, 7, and 9-12, wherein each of A^4, A^5 and A^6 is independently CR^8, wherein R^8 is hydrogen.

17. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-16, wherein Y is $–(CH_2)O–$, $–O(CH_2)–$, $–(CH_2)_2O–$, $–O(CH_2)_2–$, or $–(CH_2)_2–$.

18. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4 and 6-17, wherein at least one of W^1, W^2, W^3, and W^4 is N, optionally wherein:

each of W^1, W^2, and W^3 is independently CH or CR^4, and W^4 is N;

each of W^1, W^2, and W^4 is independently CH or CR^4, and W^3 is N;

each of W^1, W^3, and W^4 is independently CH or CR^4, and W^2 is N; or

each of W^2, W^3, and W^4 is independently CH or CR^4, and W^1 is N.

19. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4 and 6-17, wherein each of W^1, W^2, W^3, and W^4 is independently CH or CR^4.

20. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers,

and/or mixture of stereoisomers thereof, of any one of claims 1-4 and 6-19, wherein at least one of Z^1, Z^2, Z^3, and Z^4 is N, optionally wherein:

each of Z^1, Z^2, and Z^3 is independently CH or CR^5, and Z^4 is N;

each of Z^1, Z^2, and Z^4 is independently CH or CR^5, and Z^3 is N;


each of Z^1, Z^3, and Z^4 is independently CH or CR^5, and Z^2 is N; or


each of Z^2, Z^3, and Z^4 is independently CH or CR^5, and Z^1 is N.


21. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4 and 6-19, wherein each of Z^1, Z^2, Z^3, and Z^4 is independently CH or CR^5.


22. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-4 and 6-21, wherein R^5, at each occurrence, is independently R^9, halo, or CN; or each R^5 independently is halo or CN.

23. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-16, wherein R^7 is a *C*-linked imidazolyl or a *C*-linked triazolyl, each optionally substituted with 1-3 substituents independently selected from halo, CN, R^9, –OH, and $–OR^9$; optionally wherein R^7 is a *N*-methyl-substituted imidazolyl or a *N*-methyl-substituted triazolyl; optionally wherein R^7 is



,


,


or


.

24. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-23, wherein R^6 is CN, R^9, $–OR^9$, $–NR^{10}R^{11}$, or $–NR^{10}OR^9$, wherein R^9 is independently hydrogen or C_{1-3} alkyl, and wherein R^{10} and R^{11} are each independently hydrogen, C_{1-3} alkyl or C_{1-3} haloalkyl.

25. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-24, wherein:
the compound has a molecular weight (MW) of no more than 1,000 g/mol; or
the compound has a MW of no more than 900 g/mol, no more than 800 g/mol, no more than 700 g/mol, no more than 600 g/mol, or no more than 500 g/mol; or
the compound has a MW of no more than 600 g/mol; or
the compound has a MW of no more than 500 g/mol.

26. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is selected from the group consisting of:

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-hydroxy-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-hydroxy-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-amino-4^4-chloro-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-amino-4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-hydroxy-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-(methyl-d_3)-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-(methoxy-d_3)-2^1-(methyl-d_3)-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-amino-4^4-chloro-2^1-(methyl-d_3)-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-amino-4^4-chloro-2^1-cyclopropyl-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphane-4^4-carbonitrile;

3-amino-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphane-4^4-carbonitrile;

3-hydroxy-2^1-methyl-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphane-4^4-carbonitrile;

3-amino-2^1-methyl-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^2-oxo-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphane-4^4-carbonitrile;

2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2-carbonitrile;

4^4-chloro-2^2-methoxy-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-2^1-methyl-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-3-(methylamino)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-amino-4^4-chloro-2^1-methyl-3-(4-methyl-4*H*-1,2,4-triazol-3-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-bromo-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-hydroxy-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

4^6-chloro-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-4(3,5)-pyridina-1(1,3)-benzenacyclohexaphan-3-ol;

3-hydroxy-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-4(3,5)-pyridina-1(1,3)-benzenacyclohexaphane-4^6-carbonitrile;

3-hydroxy-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-4(3,5)-pyridina-1(1,3)-benzenacyclohexaphane-4^6-carbonitrile;

3-amino-2^1-(methyl-d_3)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-4(3,5)-pyridina-1(1,3)-benzenacyclohexaphane-4^6-carbonitrile;

3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^2-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-hydroxy-2^1-methyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-morpholino-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-(piperazin-1-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-(oxetan-3-ylamino)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-2^1-(2,3-dihydroxypropyl)-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-oxo-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-(methyl-d_3)-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

4^4-bromo-2^2-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

4^4-cyano-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2-carboxamide;

4^4-bromo-2^2-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-bromo-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-(oxetan-3-yloxy)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-2^1-(methyl-d_3)-3-(5-methyl-1*H*-imidazol-1-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-(methyl-d_3)-3-(4-methyl-1*H*-imidazol-1-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

3-hydroxy-3-(1-(methyl-d_3)-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

4^4-chloro-2^1-(methyl-d_3)-3-(5-methyl-1*H*-1,2,4-triazol-1-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-(methyl-d_3)-3-(3-methyl-1*H*-1,2,4-triazol-1-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-bromo-2^2-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinazolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-bromo-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinazolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,3-diamine;

4^4-bromo-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-bromo-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

4^4-bromo-2^7-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(5,3)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

3-hydroxy-2^7-methoxy-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(5,3)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-2^2-(oxetan-3-yloxy)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-4^4-carbonitrile;

3-(4-methyl-1*H*-imidazol-1-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

3-(5-methyl-1*H*-imidazol-1-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

3-amino-4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-hydroxy-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-((2-fluoroethyl)amino)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-((2-fluoroethyl)amino)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-((2-fluoroethyl)amino)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-((2-fluoroethyl)amino)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-((2-fluoroethyl)amino)-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-((2-chloroethyl)amino)-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-((2-chloroethyl)amino)-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-((2-chloroethyl)amino)-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-3-((2-chloroethyl)amino)-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-3-((2-chloroethyl)amino)-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-2^1,2^2-dihydro-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-2^1,2^2-dihydro-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-2^1,2^2-dihydro-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-2^2-one;

4^4-chloro-2^1-cyclopropyl-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-2^1,2^2-dihydro-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-7-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-7-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-ol;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-ol;

4^4-chloro-N-(2-fluoroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-N-(2-fluoroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-amine;

4^4-chloro-N-(2-fluoroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-N-(2-fluoroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-7-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-amine;

4^4-chloro-N-(2-fluoroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-N-(2-chloroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-N-(2-chloroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-amine;

4^4-chloro-N-(2-chloroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-N-(2-chloroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-7-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphan-3-amine;

4^4-chloro-N-(2-chloroethyl)-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphan-3-amine;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphane;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-5-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphane;

4-(4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphane-3-yl)morpholine;

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-7-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacycloheptaphane; and

4^4-chloro-3-(1-methyl-1*H*-imidazol-5-yl)-3-morpholino-6-oxa-2(1,7)-isoquinolina-1,4(1,3)-dibenzenacyclohexaphane;


or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, an enantiomer, a diastereomer, a racemate, a mixture of diastereomers, and/or a mixture of stereoisomers thereof.

27. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 26, which is:

3-amino-3-(1-methyl-1*H*-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-2^2,4^4-dicarbonitrile;

or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, an isotopologue, a tautomer, and/or an (*R*)- or (*S*)-enantiomer thereof.

28. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of claim 1, which is:



or a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate thereof.

29. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-26; or the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, and/or (*R*)- or (*S*)-enantiomer thereof, of claim 27; which is a racemate, a mixture of diastereomers, or a mixture of stereoisomers, or a pharmaceutically acceptable form thereof.

30. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-26; or the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, and/or (*R*)- or (*S*)-enantiomer thereof, of claim 27; which is a single enantiomer or a single diastereomer, or a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate thereof; optionally wherein the compound is a single enantiomer with an (*R*)-configuration at the R^6/R^7-substituted carbon, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, and/or a tautomer thereof; or optionally wherein the compound is a single enantiomer with an (*S*)-configuration at the R^6/R^7-substituted carbon, or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, and/or a tautomer thereof.

31. The compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers,

and/or mixture of stereoisomers thereof, of any one of claims 1-26; or the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, and/or (*R*)- or (*S*)-enantiomer thereof, of claim 27; or the compound, or the pharmaceutically acceptable salt and/or pharmaceutically acceptable solvate thereof, of claim 28; wherein the compound is in a free base form, or a pharmaceutically acceptable solvate and/or tautomer thereof.

32. A pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof, of any one of claims 1-26; or the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, and/or (*R*)- or (*S*)-enantiomer thereof, of claim 27; or the compound, or the pharmaceutically acceptable salt and/or pharmaceutically acceptable solvate thereof, of claim 28; and a pharmaceutically acceptable carrier, excipient or diluent.

33. Use of (i) the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, enantiomer, diastereomer, racemate, mixture of diastereomers, and/or mixture of stereoisomers thereof;, of any one of claims 1-26; or (ii) the compound, or the pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isotopologue, tautomer, and/or (*R*)- or (*S*)-enantiomer thereof, of claim 27; or (iii) the compound, or the pharmaceutically acceptable salt and/or pharmaceutically acceptable solvate thereof, of claim 28; or (iv) the pharmaceutical composition of claim 32, in the manufacture of a medicament for treating cancer dependent on a farnesylated protein in a subject, wherein a therapeutically effective amount of the compound or pharmaceutically acceptable form thereof, or the pharmaceutical composition, is to be administered to the subject having cancer dependent on a farnesylated protein, optionally wherein the subject is human.

34. The use of claim 33, wherein the cancer dependent on a farnesylated protein is a cancer dependent on farnesylated H-Ras protein, optionally wherein the cancer dependent on a farnesylated protein has an H-Ras protein mutation, optionally wherein the H-Ras protein mutation is or comprises a modification in a codon that encodes an amino acid substitution at a specific position selected from G12, G13, Q61, Q22, K117, and A146, and any combination thereof, in the corresponding mutant H-Ras protein;

optionally wherein: (i) the presence or absence of the H-Ras mutation has been determined by analysis of nucleic acids obtained from a sample from the subject, optionally wherein the sample is a tissue biopsy or is a tumor biopsy; or (ii) the presence or absence of the H-Ras mutation has been determined by sequencing, polymerase chain reaction (PCR), DNA microarray, mass spectrometry (MS), single nucleotide polymorphism (SNP) assay, denaturing high-performance liquid chromatography (DHPLC), or restriction fragment length polymorphism (RFLP) assay; or (iii) a combination thereof.

35. The use of claim 33 or claim 34, wherein the cancer dependent on a farnesylated protein is a cancer dependent on farnesylated N-Ras protein, optionally wherein the cancer dependent on a farnesylated protein has an N-Ras protein mutation, optionally wherein the N-Ras mutation is or comprises a modification in a codon that encodes an amino acid substitution at a specific position selected from G12, G13, Q61, Q22, K117, and A146, and any combination thereof, in the corresponding mutant N-Ras protein;

optionally wherein: (i) the presence or absence of the N-Ras mutation has been determined by analysis of nucleic acids obtained from a sample from the subject, optionally wherein the sample is a tissue biopsy or a tumor biopsy; or (ii) the presence or absence of the N-Ras mutation has been determined by sequencing, polymerase chain reaction (PCR), DNA microarray, mass spectrometry (MS), single nucleotide polymorphism (SNP) assay, denaturing high-performance liquid chromatography (DHPLC), or restriction fragment length polymorphism (RFLP) assay; or (iii) a combination thereof.

36. The use of any one of claims 33-35, wherein the cancer dependent on a farnesylated protein is:

(a) melanoma, acute myeloid leukemia (AML), thyroid carcinoma, lung adenocarcinoma, rectal carcinoma, endometrial carcinoma, or colorectal carcinoma;

(b) carcinoma, melanoma, sarcoma, or chronic granulomatous disease;

(c) thyroid cancer, head and neck cancer, urothelial cancer, salivary cancer, cancer of the upper digestive tract, bladder cancer, breast cancer, ovarian cancer, brain cancer, gastric cancer, prostate cancer, lung cancer, colon cancer, skin cancer, liver cancer, or pancreatic cancer;

(d) head and neck cancer, optionally wherein the head and neck cancer is head and neck squamous cell carcinoma (HNSCC);

(e) squamous cell carcinoma (SCC), optionally wherein the SCC is head and neck SCC (HNSCC), lung SCC (LSCC), thyroid SCC (TSCC), esophagus SCC (ESCC), bladder SCC (BSCC) or urothelial carcinoma (UC), optionally wherein the SCC is HNSCC, optionally wherein the HNSCC is HNSCC of the trachea, HNSCC of the maxilla, HNSCC of the oral cavity; or

(f) a solid tumor.